Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Stanislas DemuthNicolas CollonguesBertrand AudoinXavier AyrignacBertrand BourreJonathan CironMikael CohenRomain DeschampsFrançoise Durand-DubiefElisabeth MaillartCaroline PapeixAurélie RuetHelene ZephirRomain MarignierJerome De Sezenull nullPublished in: Neurology (2023)
This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation.